Skip to main content
SpringerLink
Log in

Safety of Preventive Oocyte Cryopreservation

  • Chapter
  • First Online:
Preventing Age Related Fertility Loss

  • 689 Accesses

Abstract

Developments in the discipline of reproductive medicine have been on a constant rise since its conception. Successful oocyte cryopreservation has been one such breakthrough, which has expanded the scope of treatment with assisted reproductive technology.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Sanchez-Serrano M, Crespo J, Mirabet V, Cobo AC, Escriba MJ, Simon C, Pellicer A. Twins born after transplantation of ovarian cortical tissue and oocyte vitrification. Fertil Steril. 2010;93(1):268.e11–3.

    Article  PubMed  Google Scholar 

  2. Cobo A, Domingo J, Perez S, Crespo J, Remohi J, Pellicer A. Vitrification, an effective new approach to oocyte banking in healthy women, could be applied in cancer patients to preserve their fertility. Clin Transl Oncol. 2008;10:268–73.

    Article  CAS  PubMed  Google Scholar 

  3. Homburg R, Van der Veen F, Silber SJ. Oocyte vitrification-women’s emancipation set in stone. Fertil Steril. 2009;91(Suppl 4):1319–20.

    Article  PubMed  Google Scholar 

  4. Macklon NS, Stouffer RL, Giudice LC, Fauser BCJM. The science behind 24 years of ovarian stimulation for in vitro fertilization. Endocr Rev. 2010;27(2):170–207.

    Article  Google Scholar 

  5. Lunenfeld B. Historical perspectives in gonadotropin therapy. Hum Reprod Update. 2004;10:453–67.

    Article  CAS  PubMed  Google Scholar 

  6. Al-Inany HG, bou-Setta AM, Aboulghar MA, et al. Highly purified hMG achieves better pregnancy rates in IVF cycles but not ICSI cycles compared with rec FSH: a meta-analysis. Gynecol Endocrinol. 2009;25:372–8.

    Article  CAS  PubMed  Google Scholar 

  7. Le Cotonnec JY, Porchet HC, Beltrami V, Howles C. Comparative pharmacokinetics of two urinary human follicle stimulating hormone preparations in healthy female and male volunteers. Hum Reprod. 1993;8(10):1604–11.

    Article  PubMed  Google Scholar 

  8. Fauser BC. Developments in human recombinant follicle stimulating hormone technology: are we going in the right direction? Hum Reprod. 1998;13(Suppl 3):36–46.

    Article  CAS  PubMed  Google Scholar 

  9. Keene JL, Matzuk MM, Otani T, Fauser BC, Galway AB, Hsueh AJ, Boime I. Expression of biologically active human follitropin in Chinese hamster ovary cells. J Biol Chem. 1989;264:4769–75.

    CAS  PubMed  Google Scholar 

  10. Van Hooff MH, Alberda AT, Huisman GJ, Zeilmaker GH, Leerentveld RA. Doubling the human menopausal gonadotrophin dose in the course of an in-vitro fertilization treatment cycle in low responders: a randomized study. Hum Reprod. 1993;8:369–73.

    Article  PubMed  Google Scholar 

  11. Al-Inany H, Abou-Setta A, Aboulghar M, Mansour R, Serour G. Efficacy and safety of human menopausal gonadotropins versus recombinant FSH: a meta-analysis. Reprod Biomed Online. 2008;16(1):81–8.

    Article  CAS  PubMed  Google Scholar 

  12. Coomarasamy A, Afnan M, Cheema D, Van der Veen F, Bossuyt P, Van Wely M. Urinary hMG versus recombinant FSH for controlled ovarian hyper stimulation following an agonist long down-regulation protocol in IVF or ICSI treatment: a systematic review and meta-analysis. Hum Reprod. 2008;23(2):310–5.

    Article  CAS  PubMed  Google Scholar 

  13. Bosch E, Vidal C, Labarta E, Simon C, Remohi J, Pellicer A. Highly purified hMG versus recombinant FSH in ovarian hyper stimulation with GnRH antagonists-a randomized study. Hum Reprod. 2008;23(10):2346–51.

    Article  CAS  PubMed  Google Scholar 

  14. Lehert P, Schertz JC, Ezcurra D. Recombinant human follicle-stimulating hormone produces more oocytes with a lower total dose per cycle in assisted reproductive technologies compared with highly purified human menopausal gonadotrophin: a meta-analysis. Reprod Biol Endocrinol. 2010;8:112.

    Article  PubMed Central  PubMed  Google Scholar 

  15. Westergaard LW, Bossuyt PM, Van der Veen F, van Wely M. Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. Cochrane Database Syst Rev. 2011;(2):CD003973.

    Google Scholar 

  16. Fares FA, Suganuma N, Nishimori K, LaPolt PS, Hsueh AJ, Boime I. Design of a long acting follitropin agonist by fusing the C-terminal sequence of the chorionic gonadotropin beta subunit to the follitropin beta subunit. Proc Natl Acad Sci U S A. 1992;89:4304–8.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Boime I, Ben-Menahem D. Glycoprotein hormone structure-function and analog design. Recent Prog Horm Res. 1999;54:271–88.

    CAS  PubMed  Google Scholar 

  18. Fauser BC, Mannaerts BM, Devroey P, Leader A, Boime I, Baird DT. Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. Hum Reprod Update. 2009;15:309–21.

    Article  CAS  PubMed  Google Scholar 

  19. Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC, ENGAGE Investigators. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod. 2009;24(12):3063–72.

    Google Scholar 

  20. Corifollitropin alfa Ensure Study Group. Corifollitropin alfa for ovarian stimulation in IVF: a randomized trial in lower-body-weight women. Reprod Biomed Online. 2010;21(1):66–76.

    Article  Google Scholar 

  21. Mahmoud Youssef MA, Van WM, Aboulfoutouh I, El-Khyat W, van der Veen F, Al-Inany H. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. Fertil Steril. 2012;97(4):876–85.

    Article  CAS  PubMed  Google Scholar 

  22. Fatemi HM, Blockeel C, Devroey P. Ovarian stimulation: today and tomorrow. Curr Pharm Biotechnol. 2012;13(3):392–7.

    Article  CAS  PubMed  Google Scholar 

  23. Fatemi H, Oberye J, Popovic-Todorovic B, Witjes H, Manaerts B, Devroey P. Corifollitropin alfa in a long GnRH agonist protocol: proof of concept trial. Fertil Steril. 2010;94(5):1992–24.

    Article  Google Scholar 

  24. Hillier SG. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod. 1994;9(2):188–91.

    Article  CAS  PubMed  Google Scholar 

  25. Chappel SC, Howles C. Reevaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod. 1991;6(9):1206–12.

    Article  CAS  PubMed  Google Scholar 

  26. Conn PM, Crowley Jr WF. Gonadotropin-releasing hormone and its analogs. Annu Rev Med. 1994;45:391–405.

    Article  CAS  PubMed  Google Scholar 

  27. Smitz J, Devroey P, Camus M, Deschacht J, Khan I, Staessen C, Van Waesberghe L, Wisanto A, Van Steirteghem AC. The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT. Hum Reprod. 1988;3:585–90.

    Article  CAS  PubMed  Google Scholar 

  28. Barbieri RL, Hornstein MD. Assisted reproduction—in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin releasing hormone analogues. Endocr Rev. 1999;20:249–52.

    CAS  PubMed  Google Scholar 

  29. Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues. J Assist Reprod Genet. 1998;15(10):599–604.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod. 1997;12(11):2359–65.

    Article  CAS  PubMed  Google Scholar 

  31. Smitz J, Devroey P, Van Steirteghem AC. Endocrinology in luteal phase and implantation. Br Med Bull. 1990;46:709–19.

    Article  CAS  PubMed  Google Scholar 

  32. Daya S. Gonadotropin releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles. Cochrane Database Syst Rev. 2000;(2):CD001299.

    Google Scholar 

  33. Pellicer A, Simon C, Miro F, Castellvi RM, Ruiz A, Ruiz M, Perez M, Bonilla-Musoles F. Ovarian response and outcome of in-vitro fertilization in patients treated with gonadotrophin releasing hormone analogues in different phases of the menstrual cycle. Hum Reprod. 1989;4:285–9.

    Article  CAS  PubMed  Google Scholar 

  34. San Roman GA, Surrey ES, Judd HL, Kerin JF. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization. Fertil Steril. 1992;58:744–9.

    Article  CAS  PubMed  Google Scholar 

  35. Chang SY, Lee CL, Wang ML, Hu ML, Lai YM, Chang MY, Soong YK. No detrimental effects in delaying initiation of gonadotropin administration after pituitary desensitization with gonadotropin releasing hormone agonist. Fertil Steril. 1993;59:183–6.

    Article  CAS  PubMed  Google Scholar 

  36. Dimitry ES, Oskarsson T, Conaghan J, Margara R, Winston RM. Beneficial effects of a 24 h delay in human chorionic gonadotrophin administration during in-vitro fertilization treatment cycles. Hum Reprod. 1991;6:944–6.

    Article  CAS  PubMed  Google Scholar 

  37. Al-Inany HG, Abou-Setta AM, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev. 2006;3:CD001750.

    Google Scholar 

  38. Klingmüller D, Schepke M, Enzweiler C, Bidlingmaier F. Hormonal responses to the new potent GnRH antagonist Cetrorelix. Acta Endocrinol. 1993;128(1):15–8.

    PubMed  Google Scholar 

  39. Varney NR, Syrop C, Kubu CS, Struchen M, Hahn S, Franzen K. Neuropsychologic dysfunction in women following leuprolide acetate induction of hypoestrogenism. J Assist Reprod Genet. 1993;10(1):53–7.

    Article  CAS  PubMed  Google Scholar 

  40. Reissmann T, Felberbaum R, Diedrich K, Engel J, Comaru-Schally AM, Schally AV. Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview. Hum Reprod. 1995;10(8):1974–81.

    Article  CAS  PubMed  Google Scholar 

  41. Kolibianakis EM, Collins J, Tarlatzis BC, Devroey P, Diedrich K, Griesinger G. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update. 2006;12(6):651–71.

    Article  CAS  PubMed  Google Scholar 

  42. Diedrich K, Diedrich C, Santos E, Zoll C, al-Hasani S, Reissmann T, Krebs D, Klingmüller D. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod. 1994;9(5):788–91.

    Google Scholar 

  43. Lee TH, Wu MY, Chen HF, Chen MJ, Ho HN, Yang YS. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration. Fertil Steril. 2005;83(6):1700–7.

    Article  CAS  PubMed  Google Scholar 

  44. Al-Inany HG, Youssef MA, Aboulghar M, Broekmans F, Sterrenburg M, Smit J, Abou-Setta AM. GnRH antagonists are safer than agonists: an update of a Cochrane review. Hum Reprod Update. 2011;17(4):435.

    Article  PubMed  Google Scholar 

  45. Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016;4:CD001750.

    PubMed  Google Scholar 

  46. Kol S, Lightman A, Hillensjo T, Devroey P, Fauser B, Tarlatzis B, Mannaerts B, Itskovitz-Eldor J. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Hum Reprod. 1999;14(9):2242–4.

    Article  CAS  PubMed  Google Scholar 

  47. Seelig AS, Al-Hasani S, Katalinic A, Schöpper B, Sturm R, Diedrich K, Ludwig M. Comparison of cryopreservation outcome with gonadotropin-releasing hormone agonists or antagonists in the collecting cycle. Fertil Steril. 2002;77(3):472–5.

    Article  PubMed  Google Scholar 

  48. Zikopoulos K, Kolibianakis EM, Camus M, Tournaye H, Van den Abbeel E, Joris H, Van Steirteghem A, Devroey P. Duration of gonadotropin-releasing hormone antagonist administration does not affect the outcome of subsequent frozen-thawed cycles. Fertil Steril. 2004;81(2):473–5.

    Article  CAS  PubMed  Google Scholar 

  49. Simon C, Oberyé J, Bellver J, Vidal C, Bosch E, Horcajadas JA, Murphy C, Adams S, Riesewijk A, Mannaerts B, Pellicer A. Similar endometrial development in oocyte donors treated with either high- or standard-dose GnRH antagonist compared to treatment with a GnRH agonist or in natural cycles. Hum Reprod. 2005;20(12):3318–27.

    Article  CAS  PubMed  Google Scholar 

  50. Kolibianakis EM, Albano C, Camus M, Tournaye H, Van Steirteghem AC, Devroey P. Initiation of gonadotropin-releasing hormone antagonist on day 1 as compared to day 6 of stimulation: effect on hormonal levels and follicular development in in vitro fertilization cycles. J Clin Endocrinol Metab. 2003;88(12):5632–7.

    Article  CAS  PubMed  Google Scholar 

  51. Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006;12(4):333–40.

    Article  CAS  PubMed  Google Scholar 

  52. Kessler M, Reddy M, Shah R, Bahl O. Structures of N- glycosidic carbohydrate units of human chorionic gonadotropin. J Biol Chem. 1979;254:7901–8.

    CAS  PubMed  Google Scholar 

  53. Kyle CV, Griffin J, Jarrett A, Odell WD. Inability to demonstrate an ultrashort loop feedback mechanism for luteinizing hormone in humans. J Clin Endocrinol Metab. 1989;69(1):170–6.

    Article  CAS  PubMed  Google Scholar 

  54. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes J. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin releasing hormone agonist. Fertil Steril. 1991;56(2):213–20.

    Article  CAS  PubMed  Google Scholar 

  55. Haning R, Strawn E, Nolten W. Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol. 1985;66(2):220–4.

    PubMed  Google Scholar 

  56. Engmann L, Benadiva C, Humaidan P. GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis. Reprod Biomed Online. 2016;32(3):274–85.

    Article  CAS  PubMed  Google Scholar 

  57. Strickland S, Beers W. Studies on the role of plasminogen activa- tor in ovulation. In vitro response of granulosa cells to gonadotro- pins, cyclic nucleotides, and prostaglandins. J Biol Chem. 1976;251(18):5694–702.

    CAS  PubMed  Google Scholar 

  58. Eppig JJ. Gonadotropin stimulation of the expansion of cumulus oophori isolated from mice: general conditions for expansion in vitro. J Exp Zool. 1979;208(1):111–20.

    Article  CAS  PubMed  Google Scholar 

  59. Zelinski-Wooten M, Hutchison J, Hess D, Wolf D, Stouffer R. Follicle stimulating hormone alone supports follicle growth and oocyte development in gonadotrophin-releasing hormone antagonist-treated monkeys. Hum Reprod. 1995;10(7):1658–66.

    Article  CAS  PubMed  Google Scholar 

  60. Yding Andersen C. Effect of FSH and its different isoforms on maturation of oocytes from pre-ovulatory follicles. Reprod Biomed Online. 2002;5(3):232–9.

    Article  CAS  PubMed  Google Scholar 

  61. Gonen Y, Balakier H, Powell W, Casper R. Use of gonadotropin releasing hormone agonist to trigger follicular maturation for in vitro fertilization. J Clin Endocrinol Metab. 1990;71(4):918–22.

    Article  CAS  PubMed  Google Scholar 

  62. Humaidan P, Papanikolaou E, Tarlatzis B. GnRHa to trigger final oocyte maturation: a time to reconsider. Hum Reprod. 2009;24(10):2389–94.

    Article  CAS  PubMed  Google Scholar 

  63. Garcia-Velasco JA, Motta L, Lopez A, Mayoral M, Cerrillo M, Pacheco A. Low-dose human chorionic gonadotropin versus estradiol/progesterone luteal phase support in gonadotropin releasing hormone agonist-triggered assisted reproductive technique cycles: understanding a new approach. Fertil Steril. 2010;94:2820–3.

    Article  CAS  PubMed  Google Scholar 

  64. Bodri D, Guillen JJ, Galindo A, Mataro D, Pujol A, Coll O. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study. Fertil Steril. 2009;91:365–71.

    Article  CAS  PubMed  Google Scholar 

  65. Santos-Ribeiro S, Polyzos NP, Stouffs K, De Vos M, Seneca S, Tournaye H, Blockeel C. Ovarian hyperstimulation syndrome after gonadotropin-releasing hormone agonist triggering and “freeze-all”: in-depth analysis of genetic predisposition. J Assist Reprod Genet. 2015;32(7):1063–8.

    Article  PubMed Central  PubMed  Google Scholar 

  66. Acevedo B, Gomez-Palomares JL, Ricciarelli E, Hernandez ER. Triggering ovulation with gonadotropin-releasing hormone agonists does not compromise embryo implantation rates. Fertil Steril. 2006;86:1682–7.

    Article  CAS  PubMed  Google Scholar 

  67. Shapiro BS, Daneshmand ST, Garner FC, Aguirre M, Ross R. Comparison of human chorionic gonadotropin and gonadotropin-releasing hormone agonist for final oocyte maturation in oocyte donor cycles. Fertil Steril. 2007;88:237–9.

    Article  CAS  PubMed  Google Scholar 

  68. Galindo A, Bodri D, Guillen JJ, Colodron M, Vernaeve V, Coll O. Triggering with HCG or GnRH agonist in GnRH antagonist treated oocyte donation cycles: a randomised clinical trial. Gynecol Endocrinol. 2009;25:60–6.

    Article  CAS  PubMed  Google Scholar 

  69. Hernandez ER, Gomez-Palomares JL, Ricciarelli E. No room for cancellation, coasting, or ovarian hyperstimulation syndrome in oocyte donation cycles. Fertil Steril. 2009;91:1358–61.

    Article  CAS  PubMed  Google Scholar 

  70. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, Benadiva C. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Fertil Steril. 2008;89:84–91.

    Article  CAS  PubMed  Google Scholar 

  71. Frydman R, Parneix I, Belaisch-Allart J, Forman R, Hazout A, Fernandez H, Testart J. LHRH agonists in IVF: different methods of utilization and comparison with previous ovulation stimulation treatments. Hum Reprod. 1988;3(4):559–61.

    Article  CAS  PubMed  Google Scholar 

  72. Fanchin R, Peltier E, Frydman R, de Ziegler D. Human chorionic gonadotropin: does it affect human endometrial morphology in vivo? Semin Reprod Med. 2001;19(1):31–5.

    Article  CAS  PubMed  Google Scholar 

  73. Papanikolaou EG, Verpoest W, Fatemi H, Tarlatzis B, Devroey P, Tournaye H. A novel method of luteal supplementation with recombinant luteinizing hormone when a gonadotropin-releasing hormone agonist is used instead of human chorionic gonadotropin for ovulation triggering: a randomized prospective proof of concept study. Fertil Steril. 2011;95(3):1174–7.

    Article  CAS  PubMed  Google Scholar 

  74. Vloeberghs V, Peeraer K, Pexsters A, D’Hooghe T. Ovarian hyperstimulation syndrome and complications of ART. Best Pract Res Clin Obstet Gynaecol. 2009;23:691–709.

    Article  PubMed  Google Scholar 

  75. Ling LP, Phoon JWL, Lau MSK, Chan JKY, Viardot-Foucault V, Tan TY, Nadarajah S, Tan HH. GnRH agonist trigger and ovarian hyperstimulation syndrome: relook at ‘freeze-all strategy’. Reprod Biomed Online. 2014;29:392–4.

    Article  CAS  PubMed  Google Scholar 

  76. Gurbuz AS, Gode F, Ozcimen N, Isik AZ. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod Biomed Online. 2014;29:541–4.

    Article  PubMed  Google Scholar 

  77. Fatemi HM, Popovic-Todorovic B, Humaidan P, Kol S, Banker M, Devroey P, Garcia-Velasco JA. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and ‘freeze-all’ approach in GnRH antagonist protocol. Fertil Steril. 2014;101:1008–11.

    Article  CAS  PubMed  Google Scholar 

  78. Maxwell KN, Cholst IN, Rosenwaks Z. The incidence of both serious and minor complications in young women undergoing oocyte donation. Fertil Steril. 2008;90(6):2165–71.

    Article  PubMed  Google Scholar 

  79. Gordon JD, Hopkins KL, Jeffrey RB, Giudice LC. Adnexal torsion: color Doppler diagnosis and laparoscopic treatment. Fertil Steril. 1994;61:383–5.

    Article  CAS  PubMed  Google Scholar 

  80. Meyer L, Murphy LA, Gumer A, Reichman DE, Rosenwaks Z, Cholst IN. Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles. Fertil Steril. 2015;104(3):637–42.

    Article  CAS  PubMed  Google Scholar 

  81. Kolibianakis E, Albano C, Camus M, Tournaye H, Van Steirteghem A, Devroey P. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril. 2004;82(1):102–7.

    Article  CAS  PubMed  Google Scholar 

  82. Melo MA, Meseguer M, Garrido N, Bosch E, Pellicer A, Remohí J. The significance of premature luteinization in an oocyte-donation programme. Hum Reprod. 2006;21(6):1503–7.

    Article  CAS  PubMed  Google Scholar 

  83. Bennett SJ, Waterstone JJ, Cheng WC, Parsons J. Complications of transvaginal ultrasound-directed follicle aspiration: a review of 2670 consecutive procedures. J Assist Reprod Genet. 1993;10:72–7.

    Article  CAS  PubMed  Google Scholar 

  84. Ludwig AK, Glawatz M, Griesinger G, et al. Perioperative and post-operative complications of transvaginal ultrasound-guided oocyte retrieval: prospective study of >1000 oocyte retrievals. Hum Reprod. 2006;21:3235–40.

    Article  CAS  PubMed  Google Scholar 

  85. Dicker D, Ashkenazi J, Feldberg D, et al. Severe abdominal complications after transvaginal ultrasonographically guided retrieval of oocytes for in vitro fertilization and embryo transfer. Fertil Steril. 1993;59:1313–5.

    Article  CAS  PubMed  Google Scholar 

  86. Tureck RW, Garcia CR, Blasco L, Mastroianni L Jr. Perioperative complications arising after transvaginal oocyte retrieval. Obstet Gynecol. 1993;81:590–3.

    CAS  PubMed  Google Scholar 

  87. Govaerts I, Devreker F, Delbaere A, et al. Short-term medical complications of 1500 oocyte retrievals for in vitro fertilization and embryo transfer. Eur J Obstet Gynecol Reprod Biol. 1998;77:239–43.

    Article  CAS  PubMed  Google Scholar 

  88. Roest J, Mous HV, Zeilmaker GH, Verhoeff A. The incidence of major clinical complications in a Dutch transport IVF programme. Hum Reprod Update. 1996;2:345–53.

    Article  CAS  PubMed  Google Scholar 

  89. Moini A, Riazi K, Amid V, et al. Endometriosis may contribute to oocyte retrieval-induced pelvic inflammatory disease: report of eight cases. J Assist Reprod Genet. 2005;22:307–9.

    Article  PubMed  Google Scholar 

  90. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J Mammary Gland Biol Neoplasia. 2002;7:3–15.

    Article  PubMed  Google Scholar 

  91. Li LL, Zhou J, Qian XJ, Chen YD. Meta-analysis on the possible association between in vitro fertilisation and cancer risk. Int J Gynecol Cancer. 2013;23:16–24.

    Article  PubMed  Google Scholar 

  92. Siristatidis C, Sergentanis TN, Kanavidis P, Trivella M, Sotiraki M, Mavromatis I, et al. Controlled ovarian hyperstimulation for IVF: impact on ovarian, endometrial and cervical cancer—a systematic review and meta-analysis. Hum Reprod Update. 2013;19:105–23.

    Article  CAS  PubMed  Google Scholar 

  93. Kessous R, Davidson E, Meirovitz M, Sergienko R, Sheiner E. The risk of female malignancies after fertility treatments: a cohort study with 25-year follow-up. J Cancer Res Clin Oncol. 2016;142:287–93.

    Article  CAS  PubMed  Google Scholar 

  94. Jensen A, Sharif H, Kjaer SK. Use of fertility drugs and risk of uterine cancer: results from a large Danish population-based cohort study. Am J Epidemiol. 2009;170:1408–14.

    Article  PubMed  Google Scholar 

  95. Lerner-Geva L, Liat LG, Rabinovici J, Jaron R, Olmer L, Liraz O, et al. Are infertility treatments a potential risk factor for can- cer development? Perspective of 30 years of follow-up. Gynecol Endocrinol. 2012;28:809–14.

    Article  PubMed  Google Scholar 

  96. Sergentanis TN, Diamantaras AA, Perlepe C, Kanavidis P, Skalki- dou A, Petridou ET. IVF and breast cancer: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:106–23.

    Article  PubMed  Google Scholar 

  97. Lundberg FE, Johansson ALV, Rodriguez-Wallberg K, Brand JS, Czene K, Hall P, Iliadou AN. Association of infertility and fertility treatment with mammographic density in a large screening-based cohort of women: a cross-sectional study. Breast Cancer Res. 2016;18:36.

    Article  PubMed Central  PubMed  Google Scholar 

  98. Stoop D, Vercammen L, Polyzos NP, de Vos M, Nekkebroeck J, De Vroey P. Effect of ovarian stimulation and oocyte retrieval on reproductive outcome in oocyte donors. Fertil Steril. 2012;97(6):0015–282.

    Article  Google Scholar 

  99. Kramer W, Schneider J, Schultz N. US oocyte donors: a retrospective study of medical and psychologic issues. Hum Reprod. 2009;24:3144–9.

    Article  CAS  PubMed  Google Scholar 

  100. Bukulmez O, Li Q, Carr BR, Leander B, Doody KM, Doody KJ. Repetitive oocyte donation does not decrease serum anti-Mullerian hormone level. Fertil Steril. 2010;94:905–12.

    Article  CAS  PubMed  Google Scholar 

  101. Kawwass JF, Kissin DM, Kulkarni AD, Creanga AA, Session DR, Callaghan WM, Jamieson DJ. Safety of assisted reproductive technology in the United States, 2000–2011. JAMA. 2015;313(1):88–90.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Shruti Nursing Home, Mumbai, India

    Shruti Parikh

  2. Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, 101 Laarbeeklaan, Brussel, 1090, Belgium

    Christophe Blockeel

Authors
  1. Shruti Parikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christophe Blockeel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christophe Blockeel .

Editor information

Editors and Affiliations

  1. Centre for Reproductive Medicine, UZ Brussel, Brussels, Belgium

    Dominic Stoop

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Parikh, S., Blockeel, C. (2018). Safety of Preventive Oocyte Cryopreservation. In: Stoop, D. (eds) Preventing Age Related Fertility Loss. Springer, Cham. https://doi.org/10.1007/978-3-319-14857-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-14857-1_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-14856-4

  • Online ISBN: 978-3-319-14857-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation